

Comparing the Availability of New Medicines in the United States and Other Countries

	New Medicines Available	Average Delay in Availability of New Medicines
Greece	16%	31 months
Ireland	41%	20 months
Belgium	44%	22 months
Czech Republic	44%	24 months
Canada	46%	15 months
France	50%	18 months
Finland	51%	16 months
Italy	51%	20 months
Japan	51%	16 months
Netherlands	53%	7 months
Denmark	54%	12 months
Austria	58%	11 months
United Kingdom	59%	18 months
Germany	63%	10 months
United States	87%	0-3 months

Source: PhRMA analysis of IQVIA Analytics Link and FDA, EMA and PMDA data. June 2020. Note: New Active Substances (NASs) approved by the FDA, EMA and/or PMDA and first launched in any country between January 2011 and December 2019. Average delay represents the time in months since global first launch among NASs that have launched in a given country. IQVIA reports only the retail channel for Greece. Updated July 2020

Comparing the Availability of New Cancer Medicines in the United States and Other Countries

	New Cancer Medicines Available	Average Delay in Availability of Cancer Medicines
Greece	16%	41 months
Ireland	53%	23 months
Belgium	55%	25 months
Czech Republic	55%	24 months
Italy	58%	21 months
Japan	58%	23 months
Canada	59%	14 months
Finland	61%	14 months
Netherlands	63%	9 months
Denmark	64%	11 months
France	67%	16 months
Austria	68%	11 months
United Kingdom	70%	12 months
Germany	73%	11 months
United States	96%	0-2 months

Source: PhRMA analysis of IQVIA Analytics Link and FDA, EMA and PMDA data. June 2020. Note: New Active Substances (NASs) approved by the FDA, EMA and/or PMDA and first launched in any country between January 2011 and December 2019. Average delay represents the time in months since global first launch among NASs that have launched in a given country. IQVIA reports only the retail channel for Greece. Updated July 2020